B-Cell-Activating Factor Affects the Occurrence of Thyroid Autoimmunity in Chronic Hepatitis C Patients Treated with Interferon Alpha
Figure 1
Clinical features (age, sex) of CHC patients. (a) patients who developed anti-TPO antibodies () at six months after the start of peg-interferon and ribavirin therapy. (b) Patients who not developed anti-TPO antibodies () at six months after the start of peg-interferon and ribavirin therapy. was statistically significant.
